These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 463255)

  • 1. Renal osteodystrophy in children with end-stage kidney failure.
    Chan JC
    Va Med; 1979 May; 106(5):384-90. PubMed ID: 463255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in vitamin D metabolism as they pertain to chronic renal disease.
    Coburn JW; Hartenbower DL; Brickman AS
    Am J Clin Nutr; 1976 Nov; 29(11):1283-99. PubMed ID: 187055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitriol oral pulse therapy in children with renal osteodystrophy.
    Cano F; Delucchi A; Wolff E; Rodriguez E; Fuentes A
    Pediatr Nephrol; 1995 Oct; 9(5):606-8. PubMed ID: 8580020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of vitamin D in the pathogenesis of renal osteodystrophy].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2004 Sep; 14(9):15-20. PubMed ID: 15577104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal osteodystrophy and growth in children undergoing CAPD].
    Ito T; Horiike S; Iitaka K
    Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):779-90. PubMed ID: 1770638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Physiopathology of renal osteodystrophy. I. Patients with kidney failure without dialysis].
    Fournier A; Bordier P; Weil B; Safar M; Idatte JM
    Presse Med (1893); 1971 Oct; 79(45):2017-21. PubMed ID: 5119047
    [No Abstract]   [Full Text] [Related]  

  • 7. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 9. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe renal osteodystrophy without elevated serum immunoreactive parathyroid hormone concentrations in hypomagnesemia due to renal magnesium wasting.
    Zelikovic I; Dabbagh S; Friedman AL; Goelzer ML; Chesney RW
    Pediatrics; 1987 Mar; 79(3):403-9. PubMed ID: 3822640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are new vitamin D analogues in renal bone disease superior to calcitriol?
    Salusky IB
    Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal osteodystrophy: role of vitamin D and parathyroid hormone].
    Drüeke T; Ulmann A
    Nouv Presse Med; 1979 May; 8(23):1901-3. PubMed ID: 223122
    [No Abstract]   [Full Text] [Related]  

  • 13. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal osteodystrophy: past and future.
    Slatopolsky E; Lopez-Hilker S; Dusso A; Brown A; Delmez J; Martin K
    Contrib Nephrol; 1990; 78():38-45; discussion 45-6. PubMed ID: 2225842
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical use of synthetic 1,25-dihydroxycholecalciferol.
    Evans IM; Boulton-Jones M; Doyle FH; Joplin GF; Lockwood M; Matthews EW; MacIntyre I
    Calcif Tissue Res; 1976 Aug; 21 Suppl():236-41. PubMed ID: 782663
    [No Abstract]   [Full Text] [Related]  

  • 16. The problem and unanswered questions. Renal osteodystrophy, soft tissue calcification, and distrubed divalent ion metabolism in chronic renal failure.
    Kleeman CR; Massry SG; Coburn JW; Popovtzer MM
    Arch Intern Med; 1969 Sep; 124(3):262-8. PubMed ID: 5806039
    [No Abstract]   [Full Text] [Related]  

  • 17. Behavior of the vitamin D endocrine system in the development of renal osteodystrophy.
    McCarthy JT; Kumar R
    Semin Nephrol; 1986 Mar; 6(1):21-30. PubMed ID: 3299575
    [No Abstract]   [Full Text] [Related]  

  • 18. [Laboratory diagnosis of renal diseases. Modern views on the pathogenesis of uremic osteodystrophy. I].
    Jelonek A
    Przegl Lek; 1974; 31(8):758-62. PubMed ID: 4409945
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
    Coburn JW; Brickman AS
    Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852
    [No Abstract]   [Full Text] [Related]  

  • 20. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
    Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
    Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.